Common Stock, par value $0.01 per share
- Symbol
- SINT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 7.01, 9.01 · 8-K
SiNtx Technologies, Inc.
SINTNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Regulation FD Disclosure
Item 2.02 Results of Operations and Financial Condition. On November 5, 2026, SINTX Technologies, Inc. (the “Company”) issued a press release providing a business update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, including certain information regarding the Company’s results of operations, financial condition and revenue outlook.…
Press release in this filing
SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization →Company context
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SINAPTIC Foot & Ankle Implant System for reconstructive surgery.
Current securities
Historical securities (1)
Registered securities in this filing
SINTX Technologies, Inc. · 8-K · Filed 2026-11-05
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02 Results of Operations and Financial Condition.
On
November 5, 2026, SINTX Technologies, Inc. (the “Company”) issued a press release providing a business update in connection
with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, including certain information regarding
the Company’s results of operations, financial condition and revenue outlook. A copy of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
7.01. Regulation FD Disclosure.
The
information contained in the press release furnished as Exhibit 99.1 also includes updates regarding the Company’s commercialization
activities, customer purchase orders, product-development programs, strategic initiatives and other business matters.
The
information furnished pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities
of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies SALT LAKE CITY, Utah - November 5, 2026 - SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter Financial Results For the three months ended September 30, 2026, total revenue increased to approximately $2.2 million, compared with $208,000 during the prior-year period Gross profit increased to approximately $1.4 million, compared with $93,000 in the prior-year quarter, with gross margin increasing to approximately 62% from 45% reflecting improved pricing, higher manufacturing volumes, and increased production efficiencies Total operating expenses decreased 13% to $3.0 million, compared with $3.4 million in the third quarter…
Open exhibit ↗